Serum biomarkers for detection of ovarian cancer

Despite medical advances and diagnostic tools including biomarker, also ovarian cancer is a fatal gynecological malignancy with high progressive, early diagnosis of ovarian cancer is really helpful intreatment and promotion of survival rate of patients. For this finding a biomarker that is specialized for ovarian tissue with high sensitivity and specificity is really need to detect early stages of ovarian cancer.Current practices for early detection of ovarian cancer include Pelvic examination, Trans-vaginal ultrasonography, FDA-Approved Screening test include Risk of Ovarian Malignancy Algorithm (ROMA) and OVA1 screening test and finally Serum biomarkers or combination of all of them. ROMA is a scoring system in combination of CA125 and HE4 combined with menopausal status which demonstrated excellent diagnostic performance for the detection of epithelial ovarian cancer, in OVA1 screening test five factor include CA125, ApoA1, B2 microglobulin, Transferrin and Transtertin (TTR), measured in blood in the same time, CA125 is one of the best and oldest biomarkers for detection of ovarian cancer and newest serum biomarkers include HE4, Kallikerin-related peptidase, Osteopontin, ApoA1, VCAM, microRNAs can be use to detect ovarian cancer in early stages

کلیدواژه ها:

Ovarian Cancer ، Cancer Diagnosis ، Cancer Prevention ، Cancer Risks ، Cancer Treatment and Management